Fourpath Capital Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,423 shares of the biopharmaceutical company's stock after selling 2,847 shares during the quarter. Fourpath Capital Management LLC's holdings in Gilead Sciences were worth $1,168,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in GILD. Newbridge Financial Services Group Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $33,000. Annis Gardner Whiting Capital Advisors LLC boosted its position in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the period. Morton Brown Family Wealth LLC purchased a new position in Gilead Sciences in the 4th quarter worth approximately $35,000. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at $35,000. Finally, Synergy Investment Management LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $40,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company's stock, valued at $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock worth $4,630,310 in the last 90 days. Corporate insiders own 0.27% of the company's stock.
Analyst Upgrades and Downgrades
GILD has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Bank of America boosted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $110.55.
Check Out Our Latest Research Report on GILD
Gilead Sciences Stock Performance
Shares of NASDAQ GILD traded down $2.91 during midday trading on Tuesday, hitting $110.09. 8,870,755 shares of the company's stock were exchanged, compared to its average volume of 7,749,498. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96. The firm has a market cap of $136.94 billion, a P/E ratio of 297.54, a PEG ratio of 0.71 and a beta of 0.29. The stock's 50 day moving average price is $105.41 and its 200-day moving average price is $101.80. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
